IS DISEASE ACTIVITY OF CARDIAC SARCOIDOSIS SUPPRESSED DURING MAINTENANCE DOSE PERIOD OF CORTICOSTEROID THERAPY? EVALUATION BY FDG-PET

Jihaeng Im,Naoki Serizawa,Kenji Fukushima,Yasutaka Imamura,Arata Nomura,Akiko Sakai,Mitsuru Momose,Michinobu Nagao,Tsuyoshi Shiga,Koichiro Abe,Nobuhisa Hagiwara

IS DISEASE ACTIVITY OF CARDIAC SARCOIDOSIS SUPPRESSED DURING MAINTENANCE DOSE PERIOD OF CORTICOSTEROID THERAPY? EVALUATION BY FDG-PET

2018

Jihaeng Im
Naoki Serizawa
Kenji Fukushima
Yasutaka Imamura
Arata Nomura
Akiko Sakai
Mitsuru Momose
Michinobu Nagao
Tsuyoshi Shiga
Koichiro Abe
Nobuhisa Hagiwara

Corticosteroid therapy is recommended for initial treatment for cardiac sarcoidosis (CS). However, optimal maintenance dose and evaluation method for activity of CS are not established. We evaluated the activity of CS by 18F-fluorodeoxyglucose PET (FDG) during maintenance dose period of

Keywords:

Therapy Evaluation
Corticosteroid
Disease
Cardiac sarcoidosis
Maintenance dose
Internal medicine
Diabetes mellitus
Medicine
Cardiology
Urology
evaluation methods
corticosteroid therapy
initial treatment
disease activity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations